Navigation Links
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:10/31/2008

Peramivir was generally safe and well-tolerated at these dose levels.

Detailed results will be submitted to an upcoming medical meeting.

-- BioCryst reported top-line results from the completed Phase 2a trial of

BCX-4208 in subjects with moderate to severe plaque psoriasis were

consistent with interim findings. BCX-4208, a potent, rationally

designed, orally available purine nucleoside phosphorylase inhibitor,

met its primary endpoint of safety and tolerability and displayed

dose-dependant reductions in peripheral blood lymphocyte counts. The

pharmacokinetic and pharmacodynamic results suggest that BCX-4208 may

have utility in diseases dependant on T-cells, B-cells or uric acid.

The Phase 2a results have been accepted for presentation at the 50th

American Society of Hematology Annual Meeting and Exposition (ASH),

which will be held in San Francisco, December 6-9, 2008.

-- The forodesine HCl pivotal trial in cutaneous T-cell lymphoma (CTCL)

continues to enroll subjects with CTCL stages IIB through IVA who have

failed three systemic therapies. The multinational study is evaluating

once daily oral forodesine HCL treatment and is being conducted in

accordance with a Special Protocol Assessment agreement between the U.S.

Food and Drug Administration and BioCryst. A laboratory study of

forodesine HCl in leukemia cells has been accepted for presentation at

ASH.

Conference Call and Web cast

BioCryst's management team will host a conference call and Web cast on Friday, October 31, 2008, at 8:30 a.m. Eastern Time to discuss the financial results and recent developments within the Company's programs. To participate in the conference call, please dial 1-800-860-2442 (United States) or 1-412-858-4600 (International). No passcode is needed for the call. The Web ca
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
2. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
3. BioCryst to Present at the JMP Healthcare Focus Conference
4. BioCryst to Present at UBS 2008 Global Life Sciences Conference
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
9. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
10. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
11. BioCryst to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... , March 25, 2015 /PRNewswire/ - SQI Diagnostics Inc. ... that, as a result of recent discussions with certain ... shares of the Company, after dealing with certain matters ... special meeting of shareholders on March 26, 2015 (the ... the election of directors will take place when the ...
(Date:3/25/2015)... 25, 2015 Accelovance, a therapeutically focused contract ... "Best Contract Research Organization" at the upcoming Vaccine Industry ... This is the eighth consecutive year ... award, winning for "Best Contract Research Organization" in 2009, ... in 2013. "We,re excited to be a ...
(Date:3/25/2015)... IL (PRWEB) March 25, 2015 Having ... in the latter part of 2014, ITRA Global proudly ... Global, the International Tenant Representative Alliance, based in the ... to representing tenants and occupiers of commercial real estate. ... estate advisory firm in Poland that exclusively advises occupiers ...
(Date:3/25/2015)... , March 25, 2015  18 piglets born ... intense research by scientists in the College of Agriculture ... represent a breakthrough in the field of genetic ... the Department of Animal & Avian Sciences (ANSC) and ... ANSC, successfully produced genome-edited pigs using a recently ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5Accelovance Nominated for 2015 Vaccine Industry Excellence (ViE) Awards 2International Organization Expands its Global Reach to Warsaw, Poland 2University of Maryland Researchers Successfully Produce Genome-edited Pigs Using Revolutionary Technology 2
... NEW YORK, April 16 NexGenix Pharmaceuticals, presented,data ... Annual Meeting of the AACR,in San Diego today. ... on NXD30001, one of several novel, radicicol-based,Hsp90 inhibitors ... in breast cancer tumor xenograft models,without evidence for ...
... April 16 Kosan Biosciences,Incorporated (Nasdaq: KOSN ... inhibitors demonstrating a high degree of target,specificity, strong ... tumor,tissue and significant antitumor activity and safety in ... protein chaperone that acts to stabilize and/or activate ...
... ROCKVILLE, Md., April 16 The Board of ... that Dr. Danong Chen has,been elected as the ... Chen,was previously the President and CEO of Tanox ... by Genentech in 2007.,Previously Dr. Chen was Vice-President ...
Cached Biology Technology:NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 2NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect 3Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 2Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 3Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR 4Danong Chen appointed CEO of Theranostics Health 2
(Date:3/16/2015)... HANOVER, Germany , March 16, 2015 /PRNewswire/ ... DERMALOG Identification Systems GmbH will present groundbreaking innovations ... Hanover, Germany . ... DERMALOG,s latest biometric innovation is well at ... the next generation e-gate made in ...
(Date:3/12/2015)... March 12, 2015 Beta ... identity and access management (IAM) solution for a ... With Beta System,s new IAM package, customers benefit ... gleaned from multiple IAM implementations across different industries. ... as well as any necessary services and consulting. ...
(Date:3/11/2015)...   The Sync Project™ today announced ... and harness music to improve health. The platform ... measurements of physiology, enabling the study of the ... populations. It is designed for medical and health ... studies and accelerate the discovery of the clinical ...
Breaking Biology News(10 mins):DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 2Introducing The Sync Project, a Global Collaboration Harnessing the Scientific Potential of Music for Health 3
... of Chicago Celiac Disease Center is hosting the 15th ... in Chicago. The symposium is the largest celiac disease ... which follows the 2011 conference in Oslo, Norway, is ... since 2006. The Chicago meeting seeks to address ...
... a continued increase in the proportion of its journal titles indexed ... JCR ), with 1,192 (approximately 77%) titles now indexed, up from ... largest share of journals in 50 categories. In the ... rank increased by 19% (4) and the number of Wiley titles ...
... Cancer Research Group (ACRG), an independent, not-for-profit company in ... The University of Hong Kong (HKU), jointly announced the ... in hepatocellular carcinoma (HCC), one of the most deadly ... . The study provides new insights into potential therapeutic ...
Cached Biology News:UChicago Celiac Disease Center to host international symposium 2Wiley announces increase in Impact Factors 2Wiley announces increase in Impact Factors 3Wiley announces increase in Impact Factors 4Wiley announces increase in Impact Factors 5Wiley announces increase in Impact Factors 6ACRG and BGI report new evidence for the genetic bases of liver cancer 2
... atoms at the 9, 10, 12, and 13 ... internal standard for the quantification of 13(S)-HODE by ... incubation of linoleic acid with plant and mammalian ... adhesion of tumor cells to the endothelium at ...
...
...
...
Biology Products: